High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
ECOG-ACRIN Cancer Research Group
Brief summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically. PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- COMPLETED
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 1150
- sponsor
- ECOG-ACRIN Cancer Research Group
- conditions
- Melanoma (Skin)
- interventions
- BIOLOGICAL: interferon alfa-2b; OTHER: observation
- start date
- 1999-03-25
- start date type
- ACTUAL
- primary completion date
- 2015-01-01
- has results
- true
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT00003641
- Published
- Jan 27, 2003
- Updated
- Sep 29, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT00003641
- Categories
- Melanoma (Skin)
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials